|Dr. Xing Zhao||Managing Director||N/A||N/A||N/A|
|Mr. Tilmann Bur||Member of Exec. Board||257k||N/A||1965|
|Mr. Matthias Meissner M.A.||Director of Corp. Communications & Investor Relations / PR||N/A||N/A||N/A|
|Dr. Ying Zhou||Managing Director||N/A||N/A||N/A|
co.don AG, a biopharmaceutical company, develops, produces, and markets biopharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. It offers Spherox, a three-dimensional cartilage cell transplant product that is used to treat cartilage defects in adult knee joints and adolescents; and co.don chondrosphere for the treatment of cartilage defects in the hip, ankle, and shoulder and elbow. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.
co.don AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.